According to the Complaint, SteadyMed Ltd. ("SteadyMed" or the "Company") is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs.
The Company’s lead drug product candidate is Trevyent, a development-stage drug-device combination product that combines SteadyMed’s PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension.
SteadyMed has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe and the Middle East.
In March 2018, Cardiome sublicensed its rights to sell Trevyent in Canada to Cipher Pharmaceuticals.
This action stems from a proposed transaction announced on April 30, 2018 (the “Proposed Transaction”), pursuant to which SteadyMed will be acquired by United Therapeutics Corporation (“Parent”) and Daniel 24043 Acquisition Corp. Ltd. (“Merger Sub,” and together with Parent, “United Therapeutics”).
On June 25, 2018, Defendants filed a proxy statement (the “Proxy Statement”) with the United States Securities and Exchange Commission (“SEC”) in connection with the Proposed Transaction. The Complaint alleges that the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading. Accordingly, Plaintiff alleges herein that Defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “1934 Act”) in connection with the Proxy Statement.
This case was voluntarily dismissed on August 20, 2018.